Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIES: Avelumab monotherapy in cisplatin-unfit metastatic or locally advanced urothelial cancer
2018-000670-29Phase 2Completed
- Sponsor
- Consorzio Oncotech
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in transitional cell carcinoma (TCC), sponsored by Consorzio Oncotech. Primary endpoint: Primary antitumor efficacy. Started Oct 2021; status: completed.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2018-000670-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000670-29.